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Edited by Jesus AvilaAbstract Here, we demonstrated that lactacystin inhibited pro-
teasome dose-dependently in HEK293 cells stably expressing
tau. Simultaneously, it induces accumulation of both non-phos-
phorylated and hyperphosphorylated tau and decreases the bind-
ing of tau to the taxol-stabilized microtubules. Lactacystin
activates glycogen synthase kinsase-3 (GSK-3) and decreases
the phosphorylation of GSK-3 at serine-9. LiCl inhibits GSK-3
and thus reverses the lactacystin-induced accumulation of the
phosphorylated tau. Lactacystin also inhibits protein phos-
phase-2A (PP-2A) and it signiﬁcantly increases the level of
inhibitor 1 of PP-2A. These results suggest that inhibition of pro-
teasome by lactacystin induces tau accumulation and activation
of GSK-3 and inhibition of PP-2A are involved.
 2006 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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The formation of neuroﬁbrillary tangles is one of the rec-
ognized hallmark lesions seen in Alzheimer disease (AD) and
other tauopathies, and the abnormally hyperphosphorylated
tau is the major proteinous component in the tangles [1,2].
Tau is a major microtubule-associated protein. The normal
function of tau is to promote microtubule assembly and sta-
bilize the formed microtubules, and thus to establish cellular
polarity and maintain the intracellular transport of neurons
[3]. When tau is hyperphosphorylated and accumulated in
the cells, it becomes incompetent in executing the above bio-
logical functions and thus leads to disruption of microtu-
bules.
The upstream factor leading to the accumulation of tau in
AD brain is still not fully understood. Previous studies have
demonstrated that, among various abnormal posttranslational
modiﬁcations, hyperphosphorylation accelerates tau accumu-
lation [4]. Tau is a phosphoprotein, and the phosphorylation
of tau is regulated by protein kinases and phosphatases.*Corresponding author. Fax: +86 27 83693883.
E-mail address: wangjz@mails.tjmu.edu.cn (J.-Z. Wang).
1 The two authors contributed equally to this work.
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doi:10.1016/j.febslet.2006.03.073Among various kinases and phosphatases, glycogen synthase
kinase-3 (GSK-3) and protein phosphatase-2A (PP-2A) are,
respectively, the crucial kinase and phosphatase for the AD-
like tau hyperphosphorylation [5–7].
In the neuroﬁbrillary tangles of AD brains, tau is not only
hyperphosphorylated but also ubiquitilated [8], suggesting a link
between the hyperphosphorylated tau and the proteasome pro-
teolytic system in the accumulation of tau. Proteasome system is
responsible for the proteolysis of the majority cellular proteins.
However, controversial results have been reported regarding to
whether or not tau protein is a substrate of the proteasome [9–
12]. We demonstrated recently that the in vitro phosphorylated
recombinant tau was proteolyzed as eﬃciently as normal tau by
20S proteasome [13]. Another recent study also showed that
phosphorylation of tau is a signal for its degradation by
ubiquitin-proteasome system [14]. As normal proteasome can
eﬃciently degrade tau protein, it is suggested that the accumula-
tion of tau may be caused by an impaired proteasome system,
which is indeed observed inADbrain [15,16]. Therefore, in addi-
tion to hyperphosphorylation, the damaged proteasomemay be
another upstream factor responsible for the accumulation of tau
in AD brain.
To investigate the role of proteasome in tau accumulation
and the underlying mechanisms, we in the present study uti-
lized lactacystin, an irreversible inhibitor of 20S proteasome,
to inhibit the proteasome activity in HEK293 cells stably
expressing tau441. And then we investigated the eﬀect of
proteasome inhibition on tau accumulation and the involve-
ment of GSK-3 and PP-2A. We have demonstrated that lact-
acystin inhibits proteasome activity dose-dependently with a
concomitant accumulation of tau and dissociation of tau
from microtubules. Lactacystin also activates GSK-3 and
inactivates PP-2A. The activation of GSK-3 involves down
regulation of the ser-9-phosphorylated kinase and the inhibi-
tion of PP-2A is relevant to the elevation of PP-2A inhibitor
1 (I1-PP-2A).2. Materials and methods
2.1. Antibodies and chemicals
Rabbit polyclonal antibodies (pAb) PS214, PS262 and PT231
against tau phosphorylated at Ser-214, Ser-262 and Thr-231 were
purchased from Biosource International (Camarillo, CA, USA).
pAb against total GSK-3b and phospho-GSK-3b at Ser-9 and
pAb against PP2A C subunit were from Cell Signaling Technology,
Inc. (Beverly, MA, USA). pAb against I1PP2A was purchased from
Santa Cruz Biotechnology, Inc. (Santa Cruz, CA, USA). pAb R134dblished by Elsevier B.V. All rights reserved.
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phosphorylated at Ser-396/404 were gifts from Dr. Inge Grundke-Iq-
bal (NYS Institute for Basic Research, SI, NY, USA) and Dr. Peter
Davies (Albert Einstein College of Medicine, Bronx, NY, USA).
mAb Tau-1 against tau non-phosphorylated at Ser198/199/202 was
from Chemicon International Inc. (Temecula, CA, USA). mAb
Tau-5 against total tau was from Lab Vision Corp. (Fremont,
CA, USA). mAb DM1A to a-tubulin were from Sigma (St. Louis,
MO, USA). Phospho-GS peptide, a speciﬁc GSK-3 substrate, was
obtained from Upstate Biotechnology Inc. (Lake Placid, NY,
USA). LiCl, a widely used inhibitor of GSK-3, and other chemicals
were from Sigma Chemical Co. (St. Louis). [c-32P]ATP was from
Beijing Yahui Biologic and Medicinal Engineering Co. (Beijing, Chi-
na). Cell culture media were from Gibico (Grand Island, NY, USA).
Lactacystin and cycloheximide was from CalBiochem (San Diego,
CA, USA), and it was dissolved in dimethyl sulfoxide (DMSO,
0.1% ﬁnal). Lipofectamine 2000 was from Invitrogen (Carlsbad,
CA, USA).2.2. Cell culture
Wild type human embryonic kidney (HEK293) cells were cultured
in DMEM supplemented with 10% fetal bovine serum and main-
tained in 37 C and 5% CO2. The cells were stably transfected with
the longest human tau (tau 441) using Lipofectamine 2000 transfec-
tion kit according to the manufacturer’s instructions. Single cell
clones were generated by selection with G418 (250 lg/ml), and the
transfection and expression of the target genes were identiﬁed by
Western blot.
2.3. Assay of proteasome activity
The proteasome activity was measured as described previously
[17]. Brieﬂy, the cells were homogenized with buﬀer containing
12.5 mM KCl, 135 mM Tris–acetate (pH 7.5), 80 mM EGTA,
6.25 mM 2-mercaptoethanol and 0.17% octyl-b-D-glucopyranoside,
and centrifuged at 12500 · g for 15 min at room temperature. Then,
the supernatant fraction was collected and protein concentration
was estimated by Bradford method [18]. To determine chymotryp-
sin-like activity of proteasome, 100 lg of proteins were incubated
for 30 min at 37 C with 100 ll of 100 mM Hepes–HCl (pH 7.5)
containing 50 lM of substrate (Ala-Ala-Phe-7-amido-4-methyl cou-
marin), the reaction was stopped by addition of 100 ll of 220 mM
sodium acetate buﬀer and placed for 30 min at 4 C. The precipi-
tated non-degraded protein was separated at 400 · g for 30 min at
4 C and 200 ll aliquot of the supernatant was mixed with 2 ml
of distilled water. Fluorescence of the samples was measured with
F 4500 Spectroﬂuorometer (Sigma) at 370 nm excitation and
430 nm emission wavelengths.
2.4. Assay of the phosphorylated tau
The phosphorylation of tau at various sites was determined by
Western blotting. In brieﬂy, cells were homogenized at the desired
time points in 80 ll RIPA buﬀer containing 50 mM Tris–HCl (pH
7.4), 150 mM NaCl, 0.5% (w/v) sodium deoxycholate, 1% (v/v)
NP-40, 0.1% (w/v) SDS, 100 lM sodium orthovanadate, 1 mM
phenylmethysulfonyl ﬂuoride and 1 lg/ml each of leupeptin, aproti-
nin and pepstatin A. The cell lysates were boiled, sonicated brieﬂy
and centrifuged for 15 min at 12500 · g. Protein concentrations in
the supernatant were determined using the bicinchoninic acid
(BCA) Protein Assay Kit (Pierce, Cheshire, UK) with the bovine
serum albumin as standard. Equal amount of proteins was isolated
on 10% SDS polyacrylamide gel electrophoresis and blotted onto
nitrocellulose membranes (Hybond C-Super, Amersham Pharmacia
Biotech, Amersham, UK). The blots were blocked in 5% (w/v)
non-fat milk powder in 10 mM Tris–HCl (pH 7.5), 150 mM NaCl,
0.02% (v/v) Tween-20 (TTBS) and probed with PS214 (1:1,000), or
PS262 (1:500), or PT231(1:1000) or Tau-1 (1:30,000), or PHF-1
(1:500), or Tau-5 (1:200), or R134d (1:5000),or DM1A (1:1000),
or I1PP2A (1:600) or PP2A C subunit (1:1000) overnight at 4 C.
The blots were developed with horseradish peroxidase-conjugated
secondary antibodies (1:5000) and visualized by enhanced chemilu-
minescent substrate kit and exposure to CL-XPosure ﬁlm (Pierce).
The immunoreactivity of tau was quantitatively analyzed by Kodak
Digital Science 1D software (Eastman Kodak Co., New Haven, CT,
USA) and expressed as mean optical density. The level of total tauwas expressed as relative level of the mean optical density against
control or normalized against b-actin as indicated in the ﬁgure
legends, and the level of the phosphorylated tau was normalized
to total tau.
2.5. Assay of microtubule-binding activity of tau
Microtubule-binding activity of tau was measured by the method de-
scribed previously [19,20]. In brief, the cells were harvested in a high-
salt reassembly buﬀer (100 mM Tris, 0.5 mM MgSO4, 1 mM EGTA,
2 mM dithiothreitol, and 750 mM NaCl, pH 6.8) supplemented with
0.1% Triton X-100, 20 lM taxol, 2 mM GTP, and a mixture of prote-
ase inhibitors (2 mM phenylmethylsulfonyl ﬂuoride, L-1-chloro-3-(4-
tosylamido)-4-phenyl-2-butanon, L-1-chloro-3-(4-tosylamido)-7-ami-
no-2-heptanone-hydrochloride, leupeptin, pepstatin A, and soy bean
trypsin inhibitor; 1 lg/ml each) at 37 C. Cell lysates were homoge-
nized with 15 strokes in a warm Dounce homogenizer and then imme-
diately centrifuged at 50000 · g for 20 min (25 C). The supernatant
(S) containing unbound tau was removed and the remaining pellet
(P) was resuspended in sample buﬀer. After measurement of the pro-
tein concentration, the samples were subjected to Western blot analysis
as above. The ratio of tau bound to microtubules (P) versus unbound
(S) was assessed by comparing the immunoreactivity of tau in these
two fractions.
2.6. Assays for kinase and phosphatase activities
Cells were lysed with 100 ml buﬀer containing 50 mM Tris–Cl (pH
7.4), 150 mM NaCl, 10 mM b-ME, 5 mM ethylenediaminetetraacetic
acid (EDTA), 1 mM PMSF, 2 mM benzamidine, and 1 lg/ml each
of leupeptin, pepstatin A and aprotinin at 4 C for 10 min. The ly-
sates were then centrifuged at 16000 · g for 15 min. Equal volume
of phosphatase inhibitor cocktail (1 mM Na3VO4 and 10 mM
NaF, pH 7.0) was added to the supernatants for assay of GSK-3
activity as described [21–23]. For the assay of PP-2A activity, phos-
phorylase-b (2 mg/ml) was phosphorylated into phosphorylase-a by
incubating it for 10 min at 30 C in 40 mM Tris–HCl (pH 8.5),
20 mM b-ME, 0.2 mM CaCl2, 15 mM MgCl2, 0.5 mM c-
32P-ATP,
and 10 mg/ml phosphorylase kinase. The product of c-32P-phosphor-
ylase was separated from free ATP on a Sephadex G-50 column,
and the protein-containing fractions were collected. The activity of
PP-2A toward c-32P-phosphorylase-a was assayed by the release of
c-32P as described previously [24,25]. The reaction was carried out
in a 20 ll reaction mixture containing 50 mM Tris (pH 7.0),
10 mM b-ME, 0.1 mM EDTA, 7.5 mM caﬀeine, 7.5 ng/ml c-32P-
phosphorylase-a, 0.2 lg/ll inhibitor 1 (PP-1 speciﬁc inhibitor), and
0.06 mg/ml cell lysates. The reaction was started by adding c-32P-
phosphorylase-a, after incubation for 30 min at 30 C, the reaction
mixture (5 ll) was spotted on a chromatography paper already spot-
ted with 10 ll stop solution, i.e., 4 mM cold ATP in 20% trichloro-
acetic acid (TCA). The released c-32P was separated from the
substrate by ascending chromatography in 5% TCA in 200 mM
NaCl, and the radioactivity was counted by liquid scintillation coun-
ter (A-5082, TECAN, Austria).
2.7. Statistical analysis
Data were analyzed with SPSS statistical software. The one-way
analysis of variance procedure followed by least signiﬁcant diﬀerence
post hoc tests was used to determine the statistical signiﬁcance of dif-
ferences of the means.3. Results
3.1. Eﬀect of proteasome inhibition on total tau and its biological
activity
HEK293 stably expressing human tau441 (HEK293/
tau441) was utilized for the study. After treatment of the cells
with 2.5, 5 and 10 lM lactacystin for 24 h, we observed that
the activity of proteasome decreased in a dose-dependent
manner (Fig. 1A). This result conﬁrms the inhibitory eﬀect
of lactacystin in the experimental system. Then we measured
the level of total tau after lactacystin treatment. It was shown
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Fig. 1. Eﬀect of proteasome inhibition on total tau and its biological activity. The chymotrypsin-like activity of proteasome was measured by using
speciﬁc peptide (A). The alteration of the total tau was detected by tau-5 (B and D) and R134d (C and E), both react with total tau. To inhibit protein
translation, we used simultaneously cycloheximide (CHX, 50 lg/ml) and lactacystin (Lac) (D and E). The alteration of the microtubule binding
activity of tau during proteasome inhibition was assessed by measuring tau in the supernatant (S) and the pellet (P) as described (F, G). Lactacystin
inhibited proteasome activity dose-dependently. In accordance with the inhibition of proteasome (N = 3), the level of tau was elevated (N = 5) and
the microtubule-binding activity (N = 3) of tau was decreased. The results are expressed as the mean ± SD; *p < 0.05, **p < 0.01, Lac vs. controls.
Q.-G. Ren et al. / FEBS Letters 580 (2006) 2503–2511 2505that the immunoreactivity of Tau-5 increased in accordance
with a decreased proteasome activity (Fig. 1B). To exclude
the possible eﬀect of protein synthesis on the increased tau le-
vel, we treated the cells simultaneously with cycloheximide
(50 lg/ml) [12] to inhibit protein translation. In this condi-
tion, we still observed a dose-dependent increase of tau
(Fig. 1D). The same results were also seen by using R134d,
another polyclonal antibody to total tau (Fig. 1C and E).
These data suggest that tau is a proteolytic substrate of pro-
teasome in HEK293/tau441 cells.To study whether the inhibition of proteasome inﬂuences
the biological activity of tau, we measured the microtu-
bule-binding capacity of tau. It was shown that the level
of tau bound to the taxol-stabilized microtubules (pellet frac-
tion) decreased while the unbound tau (supernatant fraction)
increased following the treatment of the cells with 5 and
10 lM lactacystin for 24 h (Fig. 1F). To avoid any problems
in the amount of proteins, we calculated the ratio of tau in
pellet and supernatant fractions (P/S), and similar results
were observed (Fig. 1G). This result suggests that protea-
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2506 Q.-G. Ren et al. / FEBS Letters 580 (2006) 2503–2511some inhibition impairs the biological activity of tau in bind-
ing to the microtubules.
3.2. Eﬀect of proteasome inhibition on the phosphorylated tau
The eﬀect of proteasome inhibition on the level of the phos-
phorylated tau was measured by using a panel of phosphory-
lation-dependent antibodies. It was shown that the
immunoreactivity of tau at PHF-1 epitope increased to 1.5-,
1.7-, 1.9-folds, at Ser-262 site increased to 2.0-, 2.6-, 3.1-folds,
at Thr-231 site increased to 1.6-, 1.9-, 2.0-folds, and at tau-1
epitope increased to 1.1-, 1.1-, 1.4-folds of the control levels,
respectively. After normalized to total tau (tau-5), the relative
level of the phosphorylated tau at PHF-1, Ser-262 and Thr-231
sites was still higher than that of the controls, but the relative
level of tau at tau-1 sites was decreased (Fig. 2A–D). These re-
sults suggest that proteasome degrades both phosphorylated
epitopes (PHF-1, PT231 and PS262) and non-phosphorylated
epitope (tau-1) of tau, but it is more eﬃcient to the phosphor-
ylated tau, because the accumulation of the phosphorylated
tau was more obvious when the proteasome was inhibited. It
is also suggested that the phosphorylation of tau at tau-1 epi-
tope (demonstrated by decreased staining) upon lactacystin
treatment seems more prominent than its accumulation. Treat-ment of the cells with lactacystin did not change the level of
b-actin (Fig. 2E).
3.3. The involvement of GSK-3 in the lactacystin-induced
accumulation of the phosphorylated tau
As the accumulated tau is hyperphosphorylated at some of
the GSK-3 favorite sites during proteasome inhibition, we
studied the involvement of GSK-3. We observed that the activ-
ity of GSK-3 was increased signiﬁcantly (Fig. 3A) with a con-
comitant decrease in serine-9-phosphorylated GSK-3b
(inactive form) (Fig. 3B). The total level of GSK-3b is also de-
creased (Fig. 3C). To further explore the role of GSK-3 in the
phosphorylation and accumulation of tau during proteasome
inhibition, we used LiCl to inhibit GSK-3 in the study. It
was shown that the lactacystin-induced suppression of serine-
9-phosphorylated GSK-3 was not only restored but also signif-
icantly higher than normal control after LiCl treatment
(Fig. 3D). At the same time, the accumulation of the hyper-
phosphorylated tau at PHF-1 and Thr-231 epitopes induced
by lactacystin was also partially restored by LiCl (Fig. 3F
and G). These results suggest that activation of GSK-3 is in-
volved in the lactacystin-induced accumulation of the hyper-
phosphorylated tau in the cells.
3.4. The involvement of PP-2A in lactacystin-induced
accumulation of the phosphorylated tau
PP-2A is the key phosphatase in tau dephosphorylation
[6,7], therefore, we measured the level and the activity of
PP-2A during proteasome inhibition. We observed that the
protein level of PP-2A catalytic subunit was decreased
(Fig. 4A). Then, we measured the activity of PP-2A by
c-32P-labeling assay and found that it was decreased when
proteasome activity was inhibited by lactacystin (2.5, 5 and
10 lM) (Fig. 4B). To explore the possible mechanism leading
to the inhibition of PP-2A, we measured the level of I1-PP-
2A. And we found coincidently that the level of I1-PP-2A
was increased upon lactacystin (2.5 and 10 lM) treatment
(Fig. 4C). These results suggest that proteasome may inhibit
PP-2A through upregulating I1-PP-2A, and the inhibition of
PP-2A also contributes to the lactacystin-induced accumula-
tion of tau.4. Discussion
In the present study, we have investigated the eﬀect of
proteasome inhibition on tau accumulation and the underly-
ing mechanisms. The major function of the proteasome
system in eukaryotic cells is to clean out the aggregated pro-
tein and thus to maintain the protein homeostasis [26,27]. It
has been widely observed that many neurodegenerative dis-
eases are pathologically characterized by the formation of
aggregates and inclusions of aberrant proteins [28]. These
observations imply a suboptimal functioning or defective
proteasome system in these disorders. Moreover, the impor-
tance of the proteasome system in maintaining neuronal sur-
vival is also highlighted by the studies demonstrating that
pharmacological impairment of the proteasome is suﬃcient
to induce cell death [29–31]. The activity of proteasome sys-
tem in the brain of old populations is decreased [32], and it
is further suppressed in AD brain. These studies support the
viewpoint that proteasome plays a crucial role in AD. How-
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whether tau is a substrate of proteasome [9–12]. Here, we
demonstrated that inhibition of proteasome by lactacystin,
an irreversible inhibitor of proteasome, led to accumulation
of tau, most prominently the hyperphosphorylated tau in
HEK293/tau441 cells. This result is supported by a recent
study demonstrating that phospho-tau is a better substrate
for proteasome degradation [33]. In a recent in vitro study,
we also observed that hyperphosphorylated recombinant
tau could be proteolyzed as eﬃciently as normal tau by
the proteasome [13]. The present study provides further evi-dence in the cell line that both unphosphorylated and hyper-
phosphorylated taus are substrates of the proteasome, i.e.,
proteasome in normal condition can degrade tau proteins,
suggesting that an impaired proteasome system must be at
least partially responsible for the accumulation of tau seen
in AD and other tauopathies. It was also reported previously
that proteasome inhibition by MG-132, a reversible protea-
some inhibitor, stabilizes tau inclusions in oligodendroglial
cells treated with okadaic acid [34].
As a more obvious accumulation of the hyperphosphoryl-
ated tau was observed in HEK293/441 cells during protea-
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tau kinase [5]. We observed that the activity of GSK-3 was
signiﬁcantly increased after treatment of the cells with lacta-
cystin. At the same time, the level of ser-9-phosphorylated
GSK-3 was decreased, suggesting the activation of GSK-3b.
Moreover, when LiCl was simultaneously applied, the lacta-
cystin-induced activation of GSK-3 and accumulation of
the hyperphosphorylated tau were partially restored. These
data suggest that lactacystin may activate GSK-3 and thus
leads to tau hyperphosphorylation, which contributes to the
accumulation of tau. Lithium may directly inhibit GSK-3
as a competitor of Mg2+, or it may also indirectly inhibit
the kinase through arresting the dephosphorylation at ser-9
[35]. Proteasome system possesses diﬀerent types of proteo-
lytic functions, and lactacystin inhibits its chymotrypsin-like
and trypsin-like activities. Previous study suggests that lith-
ium itself may aﬀect the chymotrypsin-like activity of protea-
some [36]. However, the proteasome-mediated degradation of
tau proteins occurs independently of the chymotrypsin-like
activity [10]. Furthermore, in our lithium alone control, we
did not see obvious change in total tau level; in a separate
experiment, we also did not see obvious change in total tau
after treatment of HEK293/tau441 cells with diﬀerent concen-
trations of lithium (data not shown). These data together sug-
gest that lithium by itself does not inﬂuence tau degradation.
We also observed that the total level of GSK-3b was also de-creased although the chemical activity of GSK-3 was signiﬁ-
cantly increased upon lactacystin treatment. In a recent
study, it was also reported that a decreased GSK-3b protein
level was parallel with an increased biochemical activity of
GSK-3 [37]. The mechanism for the activation of GSK-3 dur-
ing inhibition of proteasome is currently not understood. Pre-
vious studies in diﬀerent cell lines including COS7, HEK293
and NIH3T3 demonstrated that lactacystin could enhance
the expression of endogenous G-protein-coupled receptor ki-
nase-2 (GRK-2) [38], and GRK-2 could then inhibit the
activity of Akt [39]. The consequence of the Akt inhibition
is the activation of GSK-3 [40]. This might partially explain
the observed activation of GSK-3 in the present study.
When the activity of GSK-3 was inhibited by LiCl in this
study, the lactacystin-induced accumulation of the hyper-
phosphorylated tau was only partially restored, suggesting
the involvement of other factors. Therefore, we studied
PP-2A, a key protein phosphatase in AD-like tau hyper-
phosphorylation [6,7]. We found that the level of the cata-
lytic subunit and the biochemical activity of PP-2A were
signiﬁcantly decreased and coincidently the protein level of
I1-PP-2A was signiﬁcantly elevated upon application of lact-
acystin. The activity of PP-2A is regulated by two endoge-
nous inhibitor proteins, I1-PP-2A and I2-PP-2A [41]. Both
proteins inhibit holoenzyme of PP-2A, probably by binding
directly to the catalytic subunit, and both of them are upreg-
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I1-PP-2A and I2-PP-2A inhibit PP-2A in vitro in a non-com-
petitive mode with the substrate [43]. Studies on the meta-
bolically active rat brain slices and transgenic mice suggest
that the downregulation of PP-2A may produce hyper-
phosphorylation of tau not only by the deﬁcient dephospho-
rylation of tau, but also through the activation of several
PP2A-regulated protein kinases, including calcium/calmodu-
lin-dependent protein kinase II (CaMKII), MAP kinases,
and stress-activated protein kinases [44–46]. Therefore,
lactacystin may also inhibit PP-2A through upregulating
the I1-PP-2A, and thus contributes to the accumulation of
the hyperphosphorylated tau. This result also suggests that
I1-PP-2A may be a substrate of proteasome. Further studies
are necessary to clearly illustrate the mechanism for the
alterations of GSK-3 and PP-2A during proteasome inhibi-
tion by lactacystin.Ubiquitin-proteasome pathway (UPP) is the major intracel-
lular system for extralysosomal protein degradation [47,48]. In
the present study, we chose to inhibit 20S proteasome. Because
20S proteasome is structurally the core and functionally the
catalytic subunit of 26S proteasome [49], therefore, inhibition
of 20S proteasome is signiﬁcant for understanding the roles
of ubiquitin-proteasome system on the proteolysis of tau.
Additionally, 20S proteasome presents independently in the
cells and the amount of 20S proteasome is about 2.5-fold high-
er than that of 26S protease [50], indicating the independent
role and the signiﬁcance of 20S proteasome in the proteolysis
of intracellular proteins.
In summary, we have demonstrated in the present study that
lactacystin inhibits proteasome activity and increases the levels
of tau with a dose-dependent manner in HEK293/tau441 cell
line. The activation of GSK-3 and inhibition of PP-2A also
contributes to the lactacystin-induced accumulation of the
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Fig. 4. The involvement of PP-2A in lactacystin-induced accumulation
of the phosphorylated tau. The biochemical activity of PP-2A was
measured by c-32P-labeling assay in the presence of inhibitor 1 (inhibits
PP-1 activity) (B). The total level of PP-2A and inhibitor 1 of PP-2A
(I1-PP2A) was measured by Western blotting using polyclonal
antibody PP2A C subunit antibody and I1-PP2A. The activity and
the protein level of PP-2A were decreased while the protein level of I1-
PP2A was decreased upon lactacystin treatment. The study was carried
out without using CHX. The results are expressed as the mean ± SD
(N = 3). *p < 0.05, **p < 0.01, Lac vs. controls.
2510 Q.-G. Ren et al. / FEBS Letters 580 (2006) 2503–2511hyperphosphorylated tau. The inhibition of PP-2A by lactacy-
stin involves upregulation of I1-PP-2A.
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